<?xml version='1.0' encoding='utf-8'?>
<document id="26858332"><sentence text="Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients With Non-Small-Cell Lung Cancer."><entity charOffset="59-68" id="DDI-PubMed.26858332.s1.e0" text="Erlotinib" /></sentence><sentence text="Erlotinib depends on stomach pH for its bioavailability"><entity charOffset="0-9" id="DDI-PubMed.26858332.s2.e0" text="Erlotinib" /></sentence><sentence text=" When erlotinib is taken concurrently with a proton pump inhibitor (PPI), stomach pH increases, which results in a clinically relevant decrease of erlotinib bioavailability"><entity charOffset="6-15" id="DDI-PubMed.26858332.s3.e0" text="erlotinib" /><entity charOffset="147-156" id="DDI-PubMed.26858332.s3.e1" text="erlotinib" /><pair ddi="false" e1="DDI-PubMed.26858332.s3.e0" e2="DDI-PubMed.26858332.s3.e0" /><pair ddi="false" e1="DDI-PubMed.26858332.s3.e0" e2="DDI-PubMed.26858332.s3.e1" /></sentence><sentence text=" We hypothesized that this drug-drug interaction is reversed by taking erlotinib with the acidic beverage cola"><entity charOffset="71-80" id="DDI-PubMed.26858332.s4.e0" text="erlotinib" /></sentence><sentence text=" The effects of cola on erlotinib bioavailability in patients not treated with a PPI were also studied"><entity charOffset="24-33" id="DDI-PubMed.26858332.s5.e0" text="erlotinib" /></sentence><sentence text="" /><sentence text="In this randomized, cross-over, pharmacokinetic study in patients with non-small-cell lung cancer, we studied intrapatient differences in absorption (area under the plasma concentration time curve [AUC0-12h]) after a 7-day period of concomitant treatment with erlotinib, with or without esomeprazole, with either cola or water"><entity charOffset="260-269" id="DDI-PubMed.26858332.s7.e0" text="erlotinib" /><entity charOffset="287-299" id="DDI-PubMed.26858332.s7.e1" text="esomeprazole" /><pair ddi="false" e1="DDI-PubMed.26858332.s7.e0" e2="DDI-PubMed.26858332.s7.e0" /><pair ddi="false" e1="DDI-PubMed.26858332.s7.e0" e2="DDI-PubMed.26858332.s7.e1" /></sentence><sentence text=" At the 7th and 14th day, patients were hospitalized for 1 day for pharmacokinetic sampling" /><sentence text="" /><sentence text="Twenty-eight evaluable patients were included in the analysis" /><sentence text=" In patients treated with erlotinib and esomeprazole with cola, the mean AUC0-12h increased 39% (range, -12% to 136%; P = "><entity charOffset="26-35" id="DDI-PubMed.26858332.s11.e0" text="erlotinib" /><entity charOffset="40-52" id="DDI-PubMed.26858332.s11.e1" text="esomeprazole" /><pair ddi="false" e1="DDI-PubMed.26858332.s11.e0" e2="DDI-PubMed.26858332.s11.e0" /><pair ddi="false" e1="DDI-PubMed.26858332.s11.e0" e2="DDI-PubMed.26858332.s11.e1" /></sentence><sentence text="004), whereas in patients not treated with the PPI, the mean AUC0-12h was only slightly higher (9%; range, -10% to +30%; P = " /><sentence text="03) after erlotinib intake with cola"><entity charOffset="10-19" id="DDI-PubMed.26858332.s13.e0" text="erlotinib" /></sentence><sentence text="" /><sentence text="Cola intake led to a clinically relevant and statistically significant increase in the bioavailability of erlotinib during esomeprazole treatment"><entity charOffset="106-115" id="DDI-PubMed.26858332.s15.e0" text="erlotinib" /><entity charOffset="123-135" id="DDI-PubMed.26858332.s15.e1" text="esomeprazole" /><pair ddi="false" e1="DDI-PubMed.26858332.s15.e0" e2="DDI-PubMed.26858332.s15.e0" /><pair ddi="false" e1="DDI-PubMed.26858332.s15.e0" e2="DDI-PubMed.26858332.s15.e1" /></sentence><sentence text=" In patients not treated with the PPI, the effects of cola were marginal" /><sentence text=" These findings can be used to optimize the management of drug-drug interactions between PPIs and erlotinib"><entity charOffset="98-107" id="DDI-PubMed.26858332.s17.e0" text="erlotinib" /></sentence><sentence text="" /></document>